IPO Timeline
Broker Results (T-2)
2020-05-13
Some brokers release in afternoon
Grey Market (T-1)
2020-05-14
Afternoon
HKEX Allotment (T-1)
2020-05-14
Evening
Registrar Allotment (T-1)
2020-05-14
Evening
Listing Day (T)
2020-05-15
First day of trading
Company Overview
| Stock Name | 沛嘉醫療有限公司 - B |
|---|---|
| Stock Code | 09996 |
| Company Full Name | 沛嘉醫療有限公司 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國從事介入手術醫療器械業務，包括研發經導管瓣膜治療醫療器械及神經介入手術醫療器械。 |
| Listing Date | 2020-05-15 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省蘇州市蘇州工業園區中田巷8號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.peijiamedical.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 15.36 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 50.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 1,171,292,160 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 25.8 |
|---|---|
| First Day Open | HK$ 26.8 |
| First Day Change | 67.97% |
| First Day Volume | 93141300.0 |
| First Day Turnover | 2441970000.0 |
Use of Proceeds
| Use of Proceeds | 1、約65.0%（或1,430.2百萬港元），將撥作開發及商業化我們的核心產品TaurusOne?以及其他主要在研產品； 2、約10.0%（或220.0百萬港元），將用于我們管線中的其他在研產品的正在進行的臨床前研究及擬訂的臨床試驗、準備注冊備案及潛在商業化推出； 3、約8.0%（或176.0百萬港元），將用于加強我們的研發能力以豐富我們的產品管線，其主要包括為我們的內部研發團隊招聘及支付三年薪金予高素質人才，尤其是具有豐富設計及開發技能及經驗的工程師； 4、約10.0%（或220.0百萬港元），將用于通過潛在戰略收購、投資、合作伙伴及許可機會以擴大我們的產品組合或知識產權組合； 5、約7.0%（或154.1百萬港元），將用作營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
摩根士丹利亚洲有限公司 CE AAD291
华泰金融控股（香港）有限公司 CE AOK809
Overall Coordinators (4)
摩根士丹利亚洲有限公司 CE AAD291
华泰金融控股（香港）有限公司 CE AOK809
中银国际亚洲有限公司 CE AET863
UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (6)
摩根士丹利亚洲有限公司 CE AAD291
华泰金融控股（香港）有限公司 CE AOK809
中银国际亚洲有限公司 CE AET863
UBS Securities Hong Kong Limited CE BIN466
招银国际融资有限公司 CE AVM940
国泰君安证券（香港）有限公司 CE ABY236
Joint Lead Managers (6)
摩根士丹利亚洲有限公司 CE AAD291
华泰金融控股（香港）有限公司 CE AOK809
中银国际亚洲有限公司 CE AET863
UBS Securities Hong Kong Limited CE BIN466
招银国际融资有限公司 CE AVM940
国泰君安证券（香港）有限公司 CE ABY236
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | AIHC Master Fund | 7,741,440 HKD | — | 0.33% | — | 6 months | 2020-11-15 |
| 2 | Cormorant Asset Management, LP | 62,008,320 HKD | — | 2.65% | — | 6 months | 2020-11-15 |
| 3 | Fidelity International | 387,548,160 HKD | — | 16.54% | — | 6 months | 2020-11-15 |
| 4 | Hudson Bay Master Fund LTD | 77,506,560 HKD | — | 3.31% | — | 6 months | 2020-11-15 |
| 5 | LAV Aero Limited | 38,753,280 HKD | — | 1.65% | — | 6 months | 2020-11-15 |
| 6 | Octagon Investments Master Fund LP | 62,008,320 HKD | — | 2.65% | — | 6 months | 2020-11-15 |
| 7 | OrbiMed Funds | 77,506,560 HKD | — | 3.31% | — | 6 months | 2020-11-15 |
| 8 | Prime Capital Funds | 100,761,600 HKD | — | 4.30% | — | 6 months | 2020-11-15 |
| 9 | Rock Springs Capital Master Fund LP | 62,008,320 HKD | — | 2.65% | — | 6 months | 2020-11-15 |
| 10 | Sage Partners Master Fund | 7,741,440 HKD | — | 0.33% | — | 6 months | 2020-11-15 |
| 11 | 常春藤资产管理(香港)有限公司 | 7,741,440 HKD | — | 0.33% | — | 6 months | 2020-11-15 |
| 12 | 铭基基金 | 77,506,560 HKD | — | 3.31% | — | 6 months | 2020-11-15 |
| 13 | 新华资本管理有限公司 | 46,494,720 HKD | — | 1.98% | — | 6 months | 2020-11-15 |
| 14 | 中国国有企业结构调整基金股份有限公司 | 155,013,120 HKD | — | 6.62% | — | 6 months | 2020-11-15 |
Directors & Management
| Chairman | 張一 |
|---|---|
| Company Secretary | 周慶齡 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 張一及關連人士(19.23%);FIL Limited(8.82%);LAV Biosciences Fund IV, L.P.(6.27%);高瓴資本管理有限公司(6.16%);Matrix China Management IV, L.P.(5.86%) |
|---|
IPO Timeline
